Research highlights ZVS101e, an AAV-mediated gene replacement therapy targeting Bietti crystalline corneoretinal dystrophy (BCD). This innovative approach aims to address the underlying genetic causes of the disease.
zvs101e aav mediated gene replacement therapy for bietti crystalline corneoretinal dystrophy bcd
Original title: “ZVS101e: AAV-mediated gene replacement therapy for Bietti crystalline corneoretinal dystrophy (BCD).”